胸主动脉腔内修复术中左颈动脉-锁骨下动脉旁路的长期结局与通畅率
院内死亡率为3.7%,择期与急诊组无显著差异;LCSB相关并发症发生率为7.4%,末次随访总体通畅率为97.4%,5年通畅率达99%。结论认为LCSB作为LSA血运重建策略安全有效,急诊患者亦未显示更差的院内结局。
要点
- LCSB相关并发症发生率7.4%,末次随访总体通畅率97.4%,5年通畅率99%。
核心结论
- LCSB作为TEVAR中左锁骨下动脉血运重建策略安全有效,急诊患者亦未显示更差的院内结局。
研究设计与样本
- 比较择期与急诊组的院内结局,随访报告LCSB通畅率,并行Kaplan-Meier分析生存、免于再干预和LCSB通畅率。
主要发现
- LCSB相关并发症发生12例(7.4%),末次随访总体LCSB通畅率为97.4%。
- 因II型内漏需行LSA栓塞7例(4.5%)。
- 5年生存率87.4%,免于再干预率88.5%,LCSB通畅率99%。
临床怎么用
- LCSB可作为TEVAR中LSA血运重建的安全有效选择,急诊情况下亦未增加院内不良结局风险。
- 术后随访应关注LCSB通畅性及II型内漏导致需LSA栓塞的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Left carotid-subclavian bypass (LCSB) is a classic strategy for left subclavian artery (LSA) revascularization in thoracic endovascular aortic repair (TEVAR) patients. Its employment has been reduced in recent years due to the advent of endovascular solutions for LSA management. Data on outcomes of LCSB are lacking, especially for graft-related complications and patency at follow-up. METHODS: All patients who underwent TEVAR with LCSB from November 2005 to January 2025, in an elective or urgent setting, were retrospectively analysed in terms of pre- and intraoperative characteristics, short- and mid-term outcomes. In-hospital outcomes were compared between the urgent and elective groups. LCSB patency at follow-up imaging was reported. A Kaplan-Meier analysis was performed on survival, freedom from reintervention and LCSB patency. RESULTS: LCSB was performed in 161 patients, 36 of which (22.3%) were urgent procedures. In-hospital mortality was 3.7%, with no significant difference between the elective and the urgent group (3.2% vs 5.6% respectively, P = .491). There was a not statistically significantly higher incidence of stroke in the urgent patients (0.8% vs 5.6%, P = .057). LCSB-related complications occurred in 12 patients (7.4%). Overall LCSB patency at last available follow-up was 97.4%. LSA embolization was necessary in 7 cases (4.5%) due to type II endoleak. At 5 years, survival was 87.4%, freedom from reintervention was 88.5% and LCSB patency was 99%. CONCLUSIONS: LCSB is safe and effective as a LSA revascularization strategy. Even in urgent patients, LCSB was not linked to worse in-hospital outcomes.
引用
- Murana G, Nocera C, Di Marco L, et al. Long-Term Outcomes and Patency of Left Carotid-Subclavian Bypass in Thoracic Endovascular Aortic Repair. Eur J Cardiothorac Surg. 2025. PMID: 41206953. doi:10.1093/ejcts/ezaf391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。